In­ven­ti­va restarts PhI­II screen­ing for MASH tri­al; CD­MO an­nounces small pub­lic of­fer­ing

Plus, news about Zymeworks:

In­ven­ti­va re­sumes screen­ing in PhI­II MASH tri­al: The biotech lift­ed a vol­un­tary pause it had placed on a reg­is­tra­tional study of lan­i­fi­bra­nor in Feb­ru­ary af­ter an un­ex­pect­ed ad­verse event. The com­pa­ny has im­ple­ment­ed the rec­om­men­da­tions of an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee, in­clud­ing mon­i­tor­ing pa­tients’ liv­ers every six weeks. US-list­ed shares $IVA were up about 5% on Fri­day morn­ing. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER